Business Description
GH Research PLC
ISIN : IE000GID8VI0
Total Employee Number:
73Description
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 618.81 | |||||
Equity-to-Asset | 0.96 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -22.1 | |||||
3-Year EPS without NRI Growth Rate | -16.9 | |||||
3-Year FCF Growth Rate | -12.3 | |||||
3-Year Book Growth Rate | -2.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -41.86 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 62.52 | |||||
9-Day RSI | 65 | |||||
14-Day RSI | 63.83 | |||||
3-1 Month Momentum % | 66.1 | |||||
6-1 Month Momentum % | 90.29 | |||||
12-1 Month Momentum % | 96.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 23.04 | |||||
Quick Ratio | 23.04 | |||||
Cash Ratio | 22.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6 | |||||
Shareholder Yield % | 0.01 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -19.48 | |||||
ROA % | -18.81 | |||||
ROIC % | -399.41 | |||||
3-Year ROIIC % | 36.19 | |||||
ROC (Joel Greenblatt) % | -8450.54 | |||||
ROCE % | -19.46 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 6.22 | |||||
Price-to-Tangible-Book | 6.22 | |||||
EV-to-EBIT | -27.37 | |||||
EV-to-EBITDA | -27.54 | |||||
EV-to-Forward-EBITDA | -18.61 | |||||
EV-to-FCF | -33.68 | |||||
| Price-to-Net-Current-Asset-Value | 6.28 | |||||
| Price-to-Net-Cash | 6.41 | |||||
Earnings Yield (Greenblatt) % | -3.65 | |||||
FCF Yield % | -2.53 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GH Research PLC Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.79 | ||
| Beta | 2.0278 | ||
| 3-Year Sharpe Ratio | 0.63 | ||
| 3-Year Sortino Ratio | 1.08 | ||
| Volatility % | 68.2 | ||
| 14-Day RSI | 63.83 | ||
| 14-Day ATR (€) | 0.90439 | ||
| 20-Day SMA (€) | 19.5 | ||
| 12-1 Month Momentum % | 96.98 | ||
| 52-Week Range (€) | 9.75 - 25 | ||
| Shares Outstanding (Mil) | 68.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GH Research PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GH Research PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 127 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 36 days | ||
| General meeting for 2026 | 2026-07-31 14:00 | In 30 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 18.00 (-1.64%) | ||
| Annual report for 2025 | 2026-03-05 | 13.50 (+5.47%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 | 13.50 (+5.47%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 11.40 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-07 | 10.90 (+0.00%) | ||
| General meeting for 2025 | 2025-07-31 14:00 | 12.40 (-1.59%) | ||
| First quarter earnings results for 2025 | 2025-05-08 | 8.50 (+0.00%) |
Show
Entries
GH Research PLC Frequently Asked Questions
What is GH Research PLC(FRA:1KA)'s stock price today?
The current price of FRA:1KA is €23.00. The 52 week high of FRA:1KA is €25.00 and 52 week low is €9.75.
When is next earnings date of GH Research PLC(FRA:1KA)?
The next earnings date of GH Research PLC(FRA:1KA) is 2026-08-07 Est..
Does GH Research PLC(FRA:1KA) pay dividends? If so, how much?
GH Research PLC(FRA:1KA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on GH Research PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers